FBL17 Activators
FBL17 Activators operate through a variety of pathways, primarily involving the modulation of intracellular second messenger systems to enhance the protein's activity within its cellular context. Activation mechanisms include the elevation of cyclic AMP (cAMP) levels through direct agonism of adenylate cyclase or through inhibition of phosphodiesterases that degrade cAMP, leading to an increase in protein kinase A (PKA) activity. PKA, in turn, phosphorylates target proteins, resulting in the enhancement of FBL17's functional interactions and its role in RNA processing. Moreover, certain non-cAMP-mediated pathways also contribute to the activation of FBL17. This includes direct activation of exchange proteins directly activated by cAMP (Epac), which function independently of PKA, thereby initiating downstream signaling cascades that support the activation of FBL17, further extending the repertoire of mechanisms through which FBL17 can be regulated.
The diverse array of chemical entities that facilitate the activity of FBL17 underscores the complexity of its regulation and the multiplicity of cellular systems in which it operates. Through the engagement of G-protein coupled receptors that signal via Gs proteins, these activators initiate a cascade that culminates in elevated cAMP, which not only activates PKA but also modulates other cAMP-responsive entities. This sequence of intracellular events leads to the phosphorylation and consequent activation of FBL17, thereby bolstering its involvement in critical cellular functions. In parallel, some activators function through inhibition of specific phosphodiesterases, leading to a sustained increase in cAMP levels and a persistent activation state of FBL17 via continuous PKA signaling. Additionally, certain activators act on unique pathways, such as the direct activation of Epac, which, through its downstream effectors, facilitates the activation of FBL17.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin is an adenylate cyclase activator, increasing intracellular cyclic AMP (cAMP) levels. Elevated cAMP activates PKA, which in turn can phosphorylate and thereby increase the activity of FBL17 by enhancing its functional protein interactions within the cell. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $45.00 $130.00 $480.00 $4450.00 | 74 | |
Dibutyryl-cAMP is a membrane-permeable cAMP analog. It activates PKA, mirroring the effect of endogenous cAMP. PKA activation leads to phosphorylation events that promote FBL17 activity by facilitating its role in RNA processing. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
Isoproterenol is a non-selective beta-adrenergic receptor agonist, which increases cAMP production through Gs protein activation. This increase in cAMP enhances PKA activity, promoting the phosphorylation and consequent activation of FBL17. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4 (PDE4), which breaks down cAMP. By inhibiting PDE4, rolipram indirectly raises cAMP levels, leading to PKA-mediated phosphorylation and activation of FBL17. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, preventing the breakdown of cAMP and cGMP. By elevating cAMP, IBMX indirectly augments PKA activity, which can phosphorylate and increase the activation of FBL17. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $56.00 $156.00 $270.00 $665.00 | 37 | |
Prostaglandin E2 (PGE2) acts via E-prostanoid (EP) receptors, leading to adenylate cyclase activation and increased cAMP levels. This upsurge in cAMP boosts PKA activity, which can contribute to the phosphorylation and activation of FBL17. | ||||||
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $92.00 $277.00 $969.00 | 7 | |
Histamine, through its H2 receptor subtype, activates adenylate cyclase, increasing cAMP levels. The resulting PKA activation may enhance FBL17 activity by promoting its phosphorylation and protein-protein interactions. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $103.00 $245.00 | 8 | |
Zaprinast is a selective inhibitor of phosphodiesterase 5 (PDE5), which primarily breaks down cGMP but can also increase cAMP levels. Elevated cAMP leads to PKA activation, which may phosphorylate and activate FBL17. | ||||||
Luteolin | 491-70-3 | sc-203119 sc-203119A sc-203119B sc-203119C sc-203119D | 5 mg 50 mg 500 mg 5 g 500 g | $26.00 $50.00 $99.00 $150.00 $1887.00 | 40 | |
Luteolin is a flavonoid that can inhibit PDE4, leading to increased cAMP levels and subsequent PKA activation. This activation cascade can phosphorylate and activate FBL17, enhancing its cellular functions. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $147.00 | ||
Anagrelide is a PDE3 inhibitor, which elevates cAMP levels by preventing its breakdown. This increase in cAMP stimulates PKA, which can phosphorylate and activate FBL17, thus modulating its activity in the cell. | ||||||